Rafael Amado Sells 3,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) insider Rafael Amado sold 3,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $38.41, for a total value of $115,230.00. Following the sale, the insider now directly owns 30,834 shares of the company’s stock, valued at $1,184,333.94. This trade represents a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Rafael Amado also recently made the following trade(s):

• On Tuesday, December 31st, Rafael Amado sold 7,583 shares of Zai Lab stock. The stock was sold at an average price of $26.28, for a total value of $199,281.24.

Zai Lab Stock Up 0.2 %

ZLAB opened at $38.01 on Thursday. The firm has a market capitalization of $4.17 billion, a P/E ratio of -13.72 and a beta of 1.08. The stock’s 50 day moving average price is $30.25 and its two-hundred day moving average price is $27.52. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $39.61.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. As a group, analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current year.

Institutional Trading of Zai Lab

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZLAB. FMR LLC grew its holdings in Zai Lab by 749.1% in the 4th quarter. FMR LLC now owns 5,475,505 shares of the company’s stock valued at $143,403,000 after buying an additional 4,830,646 shares during the last quarter. RTW Investments LP acquired a new stake in shares of Zai Lab during the 4th quarter worth approximately $65,714,000. Janus Henderson Group PLC grew its holdings in shares of Zai Lab by 34.2% during the 3rd quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock worth $211,488,000 after purchasing an additional 2,232,507 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Zai Lab during the 4th quarter worth approximately $46,172,000. Finally, Wellington Management Group LLP grew its holdings in shares of Zai Lab by 18.4% during the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock worth $203,660,000 after purchasing an additional 1,312,115 shares in the last quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

Analyst Ratings Changes

ZLAB has been the subject of a number of recent research reports. Scotiabank assumed coverage on Zai Lab in a research note on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price target for the company. Cantor Fitzgerald raised Zai Lab to a “strong-buy” rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. raised their price objective on Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, March 13th. Finally, Bank of America reissued a “neutral” rating and issued a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.